Orchestra BioMed Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Orchestra BioMed Holdings, Inc.
EY’s John Babitt provided a mid-year 2022 update on medtech investment trends, and the outlook for the industry going into 2023 in this commentary for In Vivo.
Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.
Pacts In Medtech: Cook Will Sell Ambu’s Duodenoscopes; QXMedical Gets UMinnesota’s Bioresorbable Embolic
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in May and June 2019.
With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.
- Controlled Release
- Drug Delivery
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- BackBeat Medical
- Caliber Therapeutics
- Freehold Surgical
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.